

Contents

	A Personal Foreword	<i>XIII</i>
	Preface	<i>XV</i>
	List of Contributors	<i>XVII</i>
I	Introduction	<i>1</i>
1	Administrative Optimization of Proteomics Networks for Drug Development	<i>3</i>
	<i>André van Hall and Michael Hamacher</i>	
1.1	Introduction	<i>3</i>
1.2	Tasks and Aims of Administration	<i>4</i>
1.3	Networking	<i>6</i>
1.4	Evaluation of Biomarkers	<i>7</i>
1.5	A Network for Proteomics in Drug Development	<i>9</i>
1.6	Realization of Administrative Networking: the Brain Proteome Projects	<i>10</i>
1.6.1	National Genome Research Network: the Human Brain Proteome Project	<i>11</i>
1.6.2	Human Proteome Organisation: the Brain Proteome Project	<i>14</i>
1.6.2.1	The Pilot Phase	<i>15</i>
	<i>References</i>	<i>17</i>
2	Proteomic Data Standardization, Deposition and Exchange	<i>19</i>
	<i>Sandra Orchard, Henning Hermjakob, Manuela Pruess, and Rolf Apweiler</i>	
2.1	Introduction	<i>19</i>
2.2	Protein Analysis Tools	<i>21</i>
2.2.1	UniProt	<i>21</i>
2.2.2	InterPro	<i>22</i>
2.2.3	Proteome Analysis	<i>22</i>
2.2.4	International Protein Index (IPI)	<i>23</i>

2.2.5	Reactome	23
2.3	Data Storage and Retrieval	23
2.4	The Proteome Standards Initiative	24
2.5	General Proteomics Standards (GPS)	24
2.6	Mass Spectrometry	25
2.7	Molecular Interactions	27
2.8	Summary	28
	<i>References</i>	28

II Proteomic Technologies 31

3 Difference Gel Electrophoresis (DIGE): the Next Generation of Two-Dimensional Gel Electrophoresis for Clinical Research 33 *Barbara Sitek, Burghardt Scheibe, Klaus Jung, Alexander Schramm and Kai Stühler*

3.1	Introduction	34
3.2	Difference Gel Electrophoresis: Next Generation of Protein Detection in 2-DE	36
3.2.1	Application of CyDye DIGE Minimal Fluors (Minimal Labeling with CyDye DIGE Minimal Fluors)	38
3.2.1.1	General Procedure	38
3.2.1.2	Example of Use: Identification of Kinetic Proteome Changes upon Ligand Activation of Trk-Receptors	39
3.2.2	Application of Saturation Labeling with CyDye DIGE Saturation Fluors	44
3.2.2.1	General Procedure	44
3.2.2.2	Example of Use: Analysis of 1000 Microdissected Cells from PanIN Grades for the Identification of a New Molecular Tumor Marker Using CyDye DIGE Saturation Fluors	45
3.2.3	Statistical Aspects of Applying DIGE Proteome Analysis	47
3.2.3.1	Calibration and Normalization of Protein Expression Data	48
3.2.3.2	Detection of Differentially Expressed Proteins	50
3.2.3.3	Sample Size Determination	51
3.2.3.4	Further Applications	52
	<i>References</i>	52

4 Biological Mass Spectrometry: Basics and Drug Discovery Related Approaches 57 *Bettina Warscheid*

4.1	Introduction	57
4.2	Ionization Principles	58
4.2.1	Matrix-Assisted Laser Desorption/Ionization (MALDI)	58
4.2.2	Electrospray Ionization	60
4.3	Mass Spectrometric Instrumentation	62

4.4	Protein Identification Strategies	65
4.5	Quantitative Mass Spectrometry for Comparative and Functional Proteomics	67
4.6	Metabolic Labeling Approaches	69
4.6.1	¹⁵ N Labeling	70
4.6.2	Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)	71
4.7	Chemical Labeling Approaches	73
4.7.1	Chemical Isotope Labeling at the Protein Level	73
4.7.2	Stable Isotope Labeling at the Peptide Level	75
4.8	Quantitative MS for Deciphering Protein–Protein Interactions	78
4.9	Conclusions	80
	<i>References</i>	81
5	Multidimensional Column Liquid Chromatography (LC) in Proteomics – Where Are We Now?	89
	<i>Egidijus Machtejevas, Klaus K. Unger and Reinhard Ditz</i>	
5.1	Introduction	90
5.2	Why Do We Need MD-LC/MS Methods?	91
5.3	Basic Aspects of Developing a MD-LC/MS Method	92
5.3.1	General	92
5.3.2	Issues to be Considered	93
5.3.3	Sample Clean-up	94
5.3.4	Choice of Phase Systems in MD-LC	94
5.3.5	Operational Aspects	97
5.3.6	State-of-the-Art – Digestion Strategy Included	98
5.3.6.1	Multidimensional LC MS Approaches	98
5.4	Applications of MD-LC Separation in Proteomics – a Brief Survey	100
5.5	Sample Clean-Up: Ways to Overcome the “Bottleneck” in Proteome Analysis	104
5.6	Summary	109
	<i>References</i>	110
6	Peptidomics Technologies and Applications in Drug Research	113
	<i>Michael Schrader, Petra Budde, Horst Rose, Norbert Lamping, Peter Schulz-Knappe and Hans-Dieter Zucht</i>	
6.1	Introduction	114
6.2	Peptides in Drug Research	114
6.2.1	History of Peptide Research	114
6.2.2	Brief Biochemistry of Peptides	116
6.2.3	Peptides as Drugs	117
6.2.4	Peptides as Biomarkers	118
6.2.5	Clinical Peptidomics	118
6.3	Development of Peptidomics Technologies	120
6.3.1	Evolution of Peptide Analytical Methods	120

6.3.2	Peptidomic Profiling	121
6.3.3	Top-Down Identification of Endogenous Peptides	123
6.4	Applications of Differential Display Peptidomics	124
6.4.1	Peptidomics in Drug Development	124
6.4.2	Peptidomics Applied to in vivo Models	127
6.5	Outlook	129
	<i>References</i>	130
7	Protein Biochips in the Proteomic Field	137
	<i>Angelika Lücking and Dolores J. Cahill</i>	
7.1	Introduction	137
7.2	Technological Aspects	139
7.2.1	Protein Immobilization and Surface Chemistry	139
7.2.2	Transfer and Detection of Proteins	141
7.2.3	Chip Content	142
7.3	Applications of Protein Biochips	144
7.4	Contribution to Pharmaceutical Research and Development	150
	<i>References</i>	151
8	Current Developments for the In Vitro Characterization of Protein Interactions	159
	<i>Daniela Moll, Bastian Zimmermann, Frank Gesellchen and Friedrich W. Herberg</i>	
8.1	Introduction	160
8.2	The Model System: cAMP-Dependent Protein Kinase	161
8.3	Real-time Monitoring of Interactions Using SPR Biosensors	161
8.4	ITC in Drug Design	163
8.5	Fluorescence Polarization, a Tool for High-Throughput Screening	165
8.6	AlphaScreen as a Pharmaceutical Screening Tool	167
8.7	Conclusions	170
	<i>References</i>	171
9	Molecular Networks in Morphologically Intact Cells and Tissue—Challenge for Biology and Drug Development	173
	<i>Walter Schubert, Manuela Friedenberger and Marcus Bode</i>	
9.1	Introduction	173
9.2	A Metaphor of the Cell	174
9.3	Mapping Molecular Networks as Patterns: Theoretical Considerations	176
9.4	Imaging Cypher Robots	177
9.5	Formalization of Network Motifs as Geometric Objects	179
9.6	Gain of Functional Information: Perspectives for Drug Development	182
	<i>References</i>	182

III	Applications	185
10	From Target to Lead Synthesis	187
	<i>Stefan Müllner, Holger Stark, Päivi Niskanen, Erich Eigenbrodt, Sybille Mazurek and Hugo Fasold</i>	
10.1	Introduction	187
10.2	Materials and Methods	190
10.2.1	Cells and Culture Conditions	190
10.2.2	In Vitro Activity Testing	190
10.2.3	Affinity Chromatography	190
10.2.4	Electrophoresis and Protein Identification	191
10.2.5	BIAcore Analysis	191
10.2.6	Synthesis of Acyl Cyanides	192
10.2.6.1	Methyl 5-cyano-5-oxopentanoate	192
10.2.6.2	Methyl 6-cyano-6-oxohexanoate	193
10.2.6.3	Methyl-5-cyano-3-methyl-5-oxopentanoate	193
10.3	Results	193
10.4	Discussion	201
	<i>References</i>	203
11	Differential Phosphoproteome Analysis in Medical Research	209
	<i>Elke Butt and Katrin Marcus</i>	
11.1	Introduction	210
11.2	Phosphoproteomics of Human Platelets	211
11.2.1	Cortactin	213
11.2.2	Myosin Regulatory Light Chain	213
11.2.3	Protein Disulfide Isomerase	214
11.3	Identification of cAMP- and cGMP-Dependent Protein Kinase Substrates in Human Platelets	216
11.4	Identification of a New Therapeutic Target for Anti-Inflammatory Therapy by Analyzing Differences in the Phosphoproteome of Wild Type and Knock Out Mice	218
11.5	Concluding Remarks and Outlook	219
	<i>References</i>	220
12	Biomarker Discovery in Renal Cell Carcinoma Applying Proteome-Based Studies in Combination with Serology	223
	<i>Barbara Seliger and Roland Kellner</i>	
12.1	Introduction	224
12.1.1	Renal Cell Carcinoma	224
12.2	Rational Approaches Used for Biomarker Discovery	225
12.3	Advantages of Different Proteome-Based Technologies for the Identification of Biomarkers	226

- 12.4 Type of Biomarker 228
- 12.5 Proteome Analysis of Renal Cell Carcinoma Cell Lines and Biopsies 229
- 12.6 Validation of Differentially Expressed Proteins 234
- 12.7 Conclusions 235
- References* 235

- 13 Studies of Drug Resistance Using Organelle Proteomics 241**
Catherine Fenselau and Zongming Fu
- 13.1 Introduction 242
- 13.1.1 The Clinical Problem and the Proteomics Response 242
- 13.2 Objectives and Experimental Design 243
- 13.2.1 The Cell Lines 243
- 13.2.2 Organelle Isolation 244
- 13.2.2.1 Criteria for Isolation 244
- 13.2.2.2 Plasma Membrane Isolation 245
- 13.2.3 Protein Fractionation and Identification 247
- 13.2.4 Quantitative Comparisons of Protein Abundances 249
- 13.3 Changes in Plasma Membrane and Nuclear Proteins in MCF-7 Cells Resistant to Mitoxantrone 252
- References* 254

- 14 Clinical Neuroproteomics of Human Body Fluids: CSF and Blood Assays for Early and Differential Diagnosis of Dementia 259**
Jens Wiltfang and Piotr Lewczuk
- 14.1 Introduction 259
- 14.2 Neurochemical Markers of Alzheimer's Disease 260
- 14.2.1 β -Amyloid Precursor Protein (β -APP): Metabolism and Impact on AD Diagnosis 261
- 14.2.2 Tau Protein and its Phosphorylated Forms 263
- 14.2.2.1 Hyperphosphorylation of Tau as a Pathological Event 264
- 14.2.2.2 Phosphorylated Tau in CSF as a Biomarker of Alzheimer's Disease 265
- 14.2.3 Apolipoprotein E (ApoE) Genotype 266
- 14.2.4 Other Possible Factors 267
- 14.2.5 Combined Analysis of CSF Parameters 267
- 14.2.6 Perspectives: Novel Techniques to Search for AD Biomarkers – Mass Spectrometry (MS), Differential Gel Electrophoresis (DIGE), and Multiplexing 270
- 14.3 Conclusions 271
- References* 272

- 15 Proteomics in Alzheimer's Disease 279**
Michael Fountoulakis, Sophia Kossida and Gert Lubec
- 15.1 Introduction 279

15.2	Proteomic Analysis	280
15.2.1	Sample Preparation	280
15.2.2	Two-Dimensional Electrophoresis	282
15.2.3	Protein Quantification	282
15.2.4	Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectroscopy	283
15.3	Proteins with Deranged Levels and Modifications in AD	284
15.3.1	Synaptosomal Proteins	290
15.3.2	Guidance Proteins	291
15.3.3	Signal Transduction Proteins	291
15.3.4	Oxidized Proteins	292
15.3.5	Heat Shock Proteins	293
15.3.6	Proteins Enriched in Amyloid Plaques	293
15.4	Limitations	294
	<i>References</i>	294
16	Cardiac Proteomics	299
	<i>Emma McGregor and Michael J. Dunn</i>	
16.1	Heart Proteomics	300
16.1.1	Heart 2-D Protein Databases	300
16.1.2	Dilated Cardiomyopathy	300
16.1.3	Animal Models of Heart Disease	301
16.1.4	Subproteomics of the Heart	302
16.1.4.1	Mitochondria	302
16.1.4.2	PKC Signal Transduction Pathways	304
16.1.5	Proteomics of Cultured Cardiac Myocytes	305
16.1.6	Proteomic Characterization of Cardiac Antigens in Heart Disease and Transplantation	306
16.1.7	Markers of Acute Allograft Rejection	307
16.2	Vessel Proteomics	307
16.2.1	Proteomics of Intact Vessels	307
16.2.2	Proteomics of Isolated Vessel Cells	308
16.2.3	Laser Capture Microdissection	311
16.3	Concluding Remarks	312
	<i>References</i>	312
IV	To the Market	319
17	Innovation Processes	321
	<i>Sven Rügger</i>	
17.1	Introduction	321
17.2	Innovation Process Criteria	322
17.3	The Concept	322
17.4	Market Attractiveness	323

17.5	Competitive Market Position	323
17.6	Competitive Technology Position	324
17.7	Strengthen the Fit	325
17.8	Reward	325
17.9	Risk	325
17.10	Innovation Process Deliverables for each Stage	326
17.11	Stage Gate-Like Process	326
17.11.1	Designation as an Evaluation Project (EvP)	327
17.11.2	Advancement to Exploratory Project (EP)	329
17.11.3	For Advancement to Progressed Project (PP)	331
17.11.4	Advancement to Market Preparation	334
17.12	Conclusion	335
	Subject Index	337